natgillin/translations-raw huggingface dataset:
Depressive patienter udviser en række symptomer, der er forbundet med selve sygdommen.
Depressed patients display a number of symptoms that are associated with the illness itself.
Det kan derfor være vanskeligt at fastslå, hvilke symptomerne der skyldes selve sygdommen, og hvilke der skyldes behandlingen med Thymanax.
It is therefore sometimes difficult to ascertain which symptoms are a result of the illness itself and which are a result of treatment with Thymanax.
Bivirkninger er opstillet nedenfor efter frekvens ud fra følgende klassifikation: meget almindelig, (≥1/ 10), almindelig (≥1/ 100 til < 1/ 10), ikke almindelig (≥1/ 1. 000 til < 1/ 100), sjælden (≥1/ 10. 000 til < 1/ 1. 000), meget sjælden (< 1/ 10. 000) og ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Adverse reactions are listed below using the following convention: very common (≥ 1/ 10); common (≥ 1/ 100 to < 1/ 10); uncommon (≥ 1/ 1,000 to < 1/ 100); rare (≥ 1/ 10,000 to < 1/ 1,000); very rare (< 1/ 10,000), not known (cannot be estimated from the available data).
Almindelige:
Nervous system disorders:
Paræstesier
Common: headache, dizziness, somnolence, insomnia, migraine Uncommon: paraesthesia
Uskarpt syn
Uncommon: blurred vision
Kvalme, diaré, obstipation, smerter i øvre abdomen
Common: nausea, diarrhoea, constipation, upper abdominal pain
Erytematøst udslæt
Skin and subcutaneous tissue disorders Common: hyperhidrosis Uncommon: eczema Rare: erythematous rash
Rygsmerter
Musculoskeletal and connective tissue disorders Common: back pain
Almene symptomer og reaktioner på administrationsstedet Almindelig:
General disorders and administration site conditions:
Træthed
Common: fatigue
Lever og galdeveje Almindelig:
Hepato-biliary disorders:
Forhøjede ALAT - og/ eller ASAT- værdier (> 3 x øvre grænse for normalområdet) (dvs.
Common: increases (> 3 times the upper limit of the normal range) in ALAT and/ or ASAT (i. e.
1, 1% for agomelatin 25/ 50 mg vs.
1.1% on agomelatine 25/ 50 mg vs.
0, 7% for placebo).
0.7% on placebo).
Sjælden:
Rare: hepatitis
Hepatitis
Psychiatric disorders:
5 Psykiske forstyrrelser Almindelig:
5 4.9 Overdose
Under den kliniske udvikling fremkom enkelte rapporter om overdosering af agomelatin, der blev indtaget alene (op til 450 mg) eller i kombination (op til 525 mg) med andre psykofarmaka.
During the clinical development, there were a few reports of agomelatine overdose, taken alone (up to 450 mg) or in combination (up to 525 mg) with other psychotropic medicinal products.
Symptomer på overdosis var begrænsede og omfattede sløvhed og epigastralgi.
Signs and symptoms of overdose were limited and included drowsiness and epigastralgia.
Der foreligger ingen specifikke antidoter til agomelatin.
No specific antidotes for agomelatine are known.
Andre antidepressiva, ATC- kode:
Other antidepressants, ATC-code:
Agomelatin er en melatonerg agonist (MT1 - og MT2- receptorer) og en 5- HT2C- antagonist.
Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist.
Undersøgelser af binding viser, at agomelatin ikke påvirker optagelsen af monoamin og ikke har affinitet til α -, β- adrenerge, histaminerge, kolinerge, dopaminerge og benzodiazepinreceptorer.
Binding studies indicate that agomelatine has no effect on monoamine uptake and no affinity for α, β adrenergic, histaminergic, cholinergic, dopaminergic and benzodiazepine receptors.
Agomelantin udviste en antidepressiv- lignende virkning i dyremodeller for depression (tillært hjælpe - løshedstest, fortvivlelsestest, kronisk lettere stress) samt i modeller med desynkroniseret døgnrytme og modeller forbundet med stress og angst.
Agomelatine has shown an antidepressant-like effect in animal models of depression (learned helplessness test, despair test, chronic mild stress) as well as in models with circadian rhythm desynchronisation and in models related to stress and anxiety.
Thymanaxs virkning og sikkerhed ved moderat til svær depression er undersøgt i et klinisk program med 5. 800 patienter, hvoraf 3. 900 blev behandlet med Thymanax.
The efficacy and safety of Thymanax in major depressive episodes have been studied in a clinical programme including 5,800 patients of whom 3,900 were treated with Thymanax.
To forsøg med justerbar dosis og fire med fast dosis.
Six placebo controlled trials have been performed to investigate the short term efficacy of Thymanax in major depressive disorder: two flexible dose studies and four fixed dose studies.
Ved behandlingens afslutning (efter 6 eller 8 uger) sås en signifikant effekt af agomelatin 25- 50 mg i tre af de seks kortvarige dobbeltblinde, placebokontrollerede forsøg.
At the end of treatment (over 6 or 8 weeks), significant efficacy of agomelatine 25-50 mg was demonstrated in 3 of the six short-term double-blind placebo-controlled studies.
Agomelatin adskilte sig ikke fra placebo i et forsøg, hvor der var assay- følsomhed for det aktive kontrolstof, fluoxetin.
Agomelatine failed to differentiate from placebo in one study where the active control fluoxetine showed assay sensitivity.
I to andre forsøg var det ikke muligt at udlede en konklusion, da de aktive kontrolstoffer, paroxetin og fluoxetin, ikke adskilte sig fra placebo.
In two other studies, it was not possible to draw any conclusions because the active controls, paroxetine and fluoxetine, failed to differentiate from placebo.
Der blev også observeret effekt hos mere alvorligt depressive patienter (baseline HAM- D ≥ 25) i alle positive placebokontrollerede forsøg.
Efficacy was also observed in more severely depressed patients (baseline HAM-D ≥ 25) in all positive placebo-controlled studies.
Vedvarende antidepressiv effekt blev påvist i et forsøg vedrørende forebyggelse af recidiv.
The maintenance of antidepressant efficacy was demonstrated in a relapse prevention study.
Patienter, der responderede på 8/ 10 ugers akut behandling med Thymanax 25- 50 mg en gang dagligt i et åbent forsøg blev randomiseret til enten Thymanax 25- 50 mg en gang dagligt eller placebo i yderligere 6 måneder.
Patients responding to 8/ 10-weeks of acute treatment with open-label Thymanax 25-50 mg once daily were randomised to either Thymanax 25-50 mg once daily or placebo for further 6-months.
Thymanax 25- 50 mg en gang dagligt viste et statistisk signifikant bedre resultat sammenlignet med placebo (p=0, 0001) for det primære effektmål, dvs. forebyggelse af recidiverende depression målt som tid til recidiv.
Thymanax 25- 50 mg once daily demonstrated a statistically significant superiority compared to placebo (p=0.0001) on the primary outcome measure, the prevention of depressive relapse, as measured by time to relapse.
Thymanax og placebo.
The incidence of relapse during the 6-months double-blind follow up period was 22% and 47% for Thymanax and placebo, respectively.
Hos depressive patienter forlængede Thymanax 25 mg den dybe søvn (Slow Wave Sleep) uden at ændre mængden af REM- søvn (Rapid Eye Movement) eller REM- latenstiden.
In depressed patients, treatment with Thymanax 25 mg increased slow wave sleep without modification of REM (Rapid Eye Movement) sleep amount or REM latency.
6 ifølge egen vurdering signifikant forbedring af indsovningstid og søvnkvalitet uden klodsethed i dagtimerne.
From the first week of treatment, onset of sleep and the quality of sleep were significantly improved without daytime clumsiness as assessed by patients.
Hos patienter med depression i remission har en specifik komparativ undersøgelse af seksuel dysfunktion vist en numerisk tendens (ikke statistisk signifikant) til mindre seksuel dysfunktion under behandlingen med Thymanax end med venlafaxin ved måling af seksualdrift, ophidselse og orgasme ud fra scoringen på Sex Effects Scale (SEXFX).
6 In a specific sexual dysfunction comparative study with remitted depressed patients, there was a numerical trend (not statistically significant) towards less sexual emergent dysfunction than venlafaxine for Sex Effects Scale (SEXFX) drive arousal or orgasm scores on Thymanax.
Analysen af de samlede resultater fra undersøgelser baseret på Arizona Sexual Experience Scale (ASEX) viste, at Thymanax ikke var forbundet med seksuel dysfunktion.
The pooled analysis of studies using the Arizona Sexual Experience Scale (ASEX) showed that Thymanax was not associated with sexual dysfunction.
Thymanax havde en neutral virkning på legemsvægt, hjertefrekvens og blodtryk i kliniske forsøg.
Thymanax had neutral effect on body weight, heart rate and blood pressure in clinical studies.
I en undersøgelse designet til at vurdere seponeringssymptomer ved hjælp af Discontinuation Emergent Signs and Symptoms (DESS -) tjeklisten hos patienter med remitteret depression inducerede Thymanax ikke seponeringssyndrom efter brat behandlingsstop.
In a study designed to assess discontinuation symptoms by the Discontinuation Emergent Signs and Symptoms (DESS) check-list in patients with remitted depression, Thymanax did not induce discontinuation syndrome after abrupt treatment cessation.
I undersøgelser hos raske forsøgspersoner har Thymanax intet potentiale for misbrug målt på en specifik visuel analog skala eller ud fra Addiction Research Center Inventory (ARCI) 49- tjeklisten.
Thymanax has no abuse potential as measured in healthy volunteer studies on a specific visual analogue scale or the Addiction Research Center Inventory (ARCI) 49 check-list.
Absorption og biotilgængelighed:
Absorption and bioavailability:
Agomelatin absorberes hurtigt og godt (≥ 80%) efter peroral administration.
Agomelatine is rapidly and well (≥ 80%) absorbed after oral administration.
Absolut biotilgængelighed er lav (< 5% efter terapeutiske perorale doser) og med betydelig interindividuel variation.
Absolute bioavailability is low (< 5% at the therapeutic oral dose) and the interindividual variability is substantial.
Biotilgængeligheden forhøjes ved indtagelse af perorale kontraceptiva og nedsættes af rygning.
The bioavailability is increased by intake of oral contraceptives and reduced by smoking.
Maksimal plasmakoncentration nås i løbet af 1- 2 timer.
The peak plasma concentration is reached within 1 to 2 hours.
Plasmaproteinbindingen er 95% uafhængigt af koncentrationen og ændres ikke med alder eller hos patienter med nedsat nyrefunktion, men den frie fraktion fordobles hos patienter med nedsat leverfunktion.
Steady state volume of distribution is about 35 l and plasma protein binding is 95% irrespective of the concentration and is not modified with age and in patients with renal impairment but the free fraction is doubled in patients with hepatic impairment.
Isoenzymerne CYP2C9 og CYP2C19 er også involveret, men kun i ringe grad.
Following oral administration, agomelatine is rapidly metabolised mainly via hepatic CYP1A2; CYP2C9 and CYP2C19 isoenzymes are also involved but with a low contribution.
1. 100 ml/ min) og sker hovedsagligt via stofskiftet.
Elimination is rapid, the mean plasma half-life is between 1 and 2 hours and the clearance is high (about 1,100 ml/ min) and essentially metabolic.
7 Nedsat nyrefunktion:
Renal impairment:
4. 2).
No relevant modification of pharmacokinetic parameters in patients with severe renal impairment has been observed (n=8, single dose of 25 mg), but caution should be exercised in patients with severe or moderate renal impairment as only limited clinical data are available in these patients (see section 4.2).
4. 2, 4. 3 og 4. 4).
In a specific study involving cirrhotic patients with chronic mild (Child-Pugh type A) or moderate (Child-Pugh type B) liver impairment, exposure to agomelatine 25 mg was substantially increased (70- times and 140-times, respectively), compared to matched volunteers (age, weight and smoking habit) with no liver failure (see section 4.2, 4.3 and 4.4).
Etniske grupper:
7 Ethnic groups:
Hos gnavere sås en markant induktion af CYP2B og en moderat induktion af CYP1A og CYP3A fra 125 mg/ kg/ døgn, mens induktionen hos aber var beskeden for CYP2B og CYP3A med 375 mg/ kg/ døgn.
In rodents, a marked induction of CYP2B and a moderate induction of CYP1A and CYP3A were seen from 125 mg/ kg/ day whereas in monkeys the induction was slight for CYP2B and CYP3A at 375 mg/ kg/ day.
I reproduktionsforsøg hos rotter og kaniner havde agomelatin ingen virkning på fertilitet, embryoets/ fostrets udvikling, fødslen og den postnatale udvikling.
Reproduction studies in the rat and the rabbit showed no effect of agomelatine on fertility, embryofoetal development and pre- and post natal development.
I et standardbatteri af in vitro - og in vivo- genotoksiske forsøg påvistes hverken mutagent eller klastogent potentiale for agomelatin.
A battery of in vitro and in vivo standard genotoxicity assays concludes to no mutagenic or clastogenic potential of agomelatine.
I karcinogenicitetsforsøg inducerede agomelatin en stigning i incidensen af levertumorer hos rotter og mus ved en dosis, der var mindst 110 gange højere end den terapeutiske dosis.
In carcinogenicity studies agomelatine induced an increase in the incidence of liver tumours in the rat and the mouse, at a dose at least 110-fold higher than the therapeutic dose.
Undersøgelser af sikkerhedsfarmakologi viste ingen virkning af agomelatin på strømmen gennem den hurtige kaliumkanal (HERG) eller på Purkinje- cellers aktionspotentiale hos hunde.
Safety pharmacology studies showed no effect of agomelatine on hERG (human Ether à-go-go Related Gene) current or on dog Purkinje cells action potential.
Agomelatin viste ikke krampefremkaldende egenskaber ved intraperitoneale doser på op til 128 mg/ kg i mus og rotter.
Agomelatine did not show proconvulsive properties at ip doses up to 128 mg/ kg in mice and rats.
Tabletkerne: − Lactosemonohydrat − Majsstivelse − Polyvidon − Natriumstivelsesglycollat type A − Stearinsyre − Magnesiumstearat − Kolloid vandfri silica
Tablet core: − Lactose monohydrate − Maize starch − Povidone − Sodium starch glycolate type A − Stearic acid − Magnesium stearate − Silica, colloidal anhydrous
Filmovertræk: − Hypromellose − Jernoxid, gul (E172) − Glycerol
Film-coating: − Hypromellose − Yellow iron oxide (E172) − Glycerol − Macrogol − Magnesium stearate − Titanium dioxide (E171)
3 år.
8 3 years.
Aluminium/ PVC blisterkort pakket i karton (kalender).
Aluminium/ PVC blister packed in cardboard boxes (calendar).
Wicklow Irland
Wicklow Ireland
DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/ FORNYELSE AF TILLADELSEN
9 DATE OF THE FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
Yderligere information om dette lægemiddel er tilgængelig på Det europæiske Lægemiddelagenturs (EMEA’ s) hjemmeside: http: // www. emea. europa. eu /.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/.
FREMSTILLERE ANSVARLIGE FOR BATCHFRIGIVELSE
10 A MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Les Laboratoires Servier Industrie, 905, route de Saran – 45520 Gidy, Frankrig Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co.
Les Laboratoires Servier Industrie, 905, route de Saran – 45520 Gidy, France Servier (Ireland) Industries Ltd, Gorey Road - Arklow - Co.
Wicklow, Irland Przedsiebiorstwo Farmaceutyczne ANPHARM S. A., ul. Annopol 6B – 03- 236 Warszawa, Polen
Wicklow, Ireland Przedsiebiorstwo Farmaceutyczne ANPHARM S. A., ul. Annopol 6B – 03-236 Warszawa, Poland
- Retningslinjer for leverfunktionsscreening (behov for at kontrollere leverfunktionen hos alle
- Guidance for hepatic function screening (Need to perform liver function tests in all patients: at initiation
11 • ANDRE BETINGELSER
11 • OTHER CONDITIONS
System til lægemiddelovervågning (pharmacovigilance)
Pharmacovigilance system
Indehaveren af markedsføringstilladelsen skal sikre, at lægemiddelovervågningssystemet (som beskrevet i version 4. 0, der indgik i modul 1. 8. 1 i ansøgningen om markedsføringstilladelse) er indført og i brug såvel før som under markedsføring af lægemidlet.
The MAH must ensure that the system of pharmacovigilance, as described in version 4.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Indehaveren af markedsføringstilladelsen forpligter sig til at gennemføre de undersøgelser og supplerende aktiviteter i forbindelse med lægemiddelovervågning, der beskrives i lægemiddelovervågningsplanen som vedtaget i version 4. 0 af risikostyringsplanen (RMP), og som indgik i modul 1. 8. 2 i ansøgningen om markedsføringstilladelse og senere opdateringer af risikostyringsplanen godkendt af CHMP (udvalget for humanmedicinske lægemidler).
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the version 4.0 of the Risk Management Plan (RMP) presented in the module 1.8.2 of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP.
I henhold til CHMP’ s retningslinjer for risikostyringssystemer til lægemidler til humant brug skal den opdaterede risikostyringsplan indsendes samtidig med den næste periodiske rapport til opdatering af sikkerhed (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
Desuden skal der indsendes en opdateret risikostyringsplan: • når der modtages nye oplysninger, der kan have indflydelse på den aktuelle sikkerhedsspecifikation, plan for lægemiddelovervågning eller foranstaltninger mhp. risikominimering, • inden for 60 dage efter passering af en vigtig milepæl (inden for lægemiddelovervågning eller risikominimering), • på opfordring fra EMEA.
In addition, an updated RMP should be submitted • when new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • at the request of the EMEA
Thymanax 25 mg filmovertrukne tabletter Agomelatin.
Thymanax 25 mg film-coated tablets Agomelatine
Hver tablet indeholder 25 mg agomelatin.
Each tablet contains 25 mg of agomelatine.
7 filmovertrukne tabletter 14 filmovertrukne tabletter 28 filmovertrukne tabletter 42 filmovertrukne tabletter 56 filmovertrukne tabletter 84 filmovertrukne tabletter 98 filmovertrukne tabletter 100 filmovertrukne tabletter
7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 42 film-coated tablets 56 film-coated tablets 84 film-coated tablets 98 film-coated tablets 100 film-coated tablets
Til indtagelse gennem munden.
Oral use.
Servier (Ireland) Industries Ltd, Gorey Road, Arklow, Co.
Servier (Ireland) Industries Ltd, Gorey Road, Arklow, Co.
Wicklow Ireland
Wicklow Ireland
Thymanax 25 mg.
Thymanax 25 mg
16 MINDSTEKRAV TIL MÆRKNING PÅ BLISTERKORT ELLER BLISTERSTRIPS
16 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
{BLISTERKORT}
BLISTER
- Lægen har ordineret Thymanax til Dem personligt.
- This medicine has been prescribed for you.
- Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller De får bivirkninger, som
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please
Virkning og anvendelse 2.
What Thymanax is and what it is used for 2.
Det skal De vide, før De begynder at tage Thymanax 3.
Before you take Thymanax 3.
Sådan skal De tage Thymanax 4.
How to take Thymanax 4.
Opbevaring 6.
Possible side effects 5 How to store Thymanax 6.
VIRKNING OG ANVENDELSE
WHAT THYMANAX IS AND WHAT IT IS USED FOR
Thymanax hører til en gruppe medicin, der kaldes antidepressiva, og De har fået Thymanax til behandling af en depression.
Thymanax belongs to a group of medicines called antidepressants and you have been given Thymanax to treat your depression.
Symptomerne på en depression er forskellige hos forskellige personer, men vil ofte omfatte en uhyre tristhed, en følelse af ikke at slå til, manglende lyst til at gøre selv det, man bedst kan lide, søvn - forstyrrelser, en fornemmelse af at køre på nedsat kraft, angst og vægtforandringer.
The symptoms of depression vary from one person to another, but often include deep sadness, feelings of worthlessness, loss of interest in favourite activities, sleep disturbances, feeling of being slowed down, feelings of anxiety, changes in weight.
DET SKAL DE VIDE, FØR DE BEGYNDER AT TAGE THYMANAX
BEFORE YOU TAKE THYMANAX
Tag ikke Thymanax
Do not take Thymanax
- hvis De er overfølsom (allergisk) over for agomelatin eller et af de øvrige indholdsstoffer (se
- if you are allergic (hypersensitive) to agomelatine or any of the other ingredients of Thymanax (see
’ Thymanax indeholder ’ i afsnit 6).
‘ What Thymanax contains ’ in section 6).
- hvis De tager fluvoxamin (et andet middel mod depression) eller ciprofloxacin (et
- if you are taking fluvoxamine (another medicine used in the treatment of depression) or
antibiotikum).
ciprofloxacin (an antibiotic).
Vær ekstra forsigtig med at tage Thymanax Der kan være grunde til, at Thymanax ikke er det rette middel til Dem:
Take special care with Thymanax There could be some reasons why Thymanax may not be suitable for you:
- Hvis De allerede har haft, eller hvis De får, maniske symptomer (en periode med unormalt
- If you have already experienced or if you develop manic symptoms (a period of abnormally high
Tal med lægen, inden De begynder at tage denne medicin eller fortsætter med at tage den.
excitability and emotions) talk to your doctor before you start taking this medicine or continue with this medicine.
- Hvis De tager medicin, som vides at påvirke leveren.
- If you are taking medicine known to affect the liver.
Spørg lægen til råds om, hvilken medicin
Ask your doctor for advice on which medicine
det drejer sig om.
that is.
Deres læge vil derfor få foretaget laboratorieundersøgelser for at kontrollere, at Deres lever fungerer korrekt ved indledning af behandlingen og derefter jævnligt i løbet af behandlingen.
19 properly at the initiation of the treatment and then periodically during treatment.
Ud fra en evaluering af disse undersøgelser vil lægen afgøre, om De bør fortsætte med at bruge Thymanax eller ej (se også afsnit 3, ’ Sådan skal De tage Thymanax ’).
Based on the evaluation of these tests the doctor will decide whether you should continue using Thymanax or not (see also under “ How to take Thymanax ” in section 3).
- Hvis De lider af demens, vil Deres læge foretage en individuel vurdering af, om det er sikkert
- If you are suffering from dementia, your doctor will make an individual evaluation of whether it is
for Dem at tage Thymanax.
safe for you to take Thymanax.
19 Thymanax er ikke beregnet til brug hos børn og unge (under 18 år).
Thymanax is not intended for use in children and adolescents (under 18 years old).
Selvmordstanker og forværring af depressionen Under en depression kan man af og til tænke på at skade sig selv eller begå selvmord.
Thoughts of suicide and worsening of your depression If you are depressed you can sometimes have thoughts of harming or killing yourself.
De kan være mere tilbøjelig til at få disse tanker:
You may be more likely to think like this:
- hvis De tidligere har haft selvmordstanker eller tænkt på at skade Dem selv.
- if you have previously had thoughts about killing or harming yourself.
Oplysninger fra kliniske forsøg har vist en øget risiko for
Information from clinical trials has shown an increased risk of suicidal
selvmordsadfærd hos yngre personer under 25 år med psykiske lidelser og i behandling med et middel mod depression.
behaviour in young adults (aged less than 25 years) with psychiatric conditions who were being treated with an antidepressant.
De kan f. eks. bede dem sige til, hvis de mener, at Deres depression er blevet værre, eller hvis de er bekymrede over ændringer i Deres opførsel.
You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.